450 reports of this reaction
6.2% of all DOXYLAMINE SUCCINATE reports
#2 most reported adverse reaction
SOMNOLENCE is the #2 most commonly reported adverse reaction for DOXYLAMINE SUCCINATE, manufactured by Chattem, Inc.. There are 450 FDA adverse event reports linking DOXYLAMINE SUCCINATE to SOMNOLENCE. This represents approximately 6.2% of all 7,212 adverse event reports for this drug.
Patients taking DOXYLAMINE SUCCINATE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is moderately reported among DOXYLAMINE SUCCINATE users, representing a notable but not dominant share of adverse events.
In addition to somnolence, the following adverse reactions have been reported for DOXYLAMINE SUCCINATE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 450 FDA reports for DOXYLAMINE SUCCINATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 6.2% of all adverse event reports for DOXYLAMINE SUCCINATE, making it one of the most commonly reported side effect.
If you experience somnolence while taking DOXYLAMINE SUCCINATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.